Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with Fidaxomicin. If a severe hypersensitivity reaction occurs, Fidaxomicin should be discontinued and appropriate therapy should be instituted. Some patients with hypersensitivity reactions to Fidaxomicin also reported a history of allergy to other macrolides. Physicians prescribing Fidaxomicin to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions.
Fidaxomicin is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin. Fidaxomicin has not been studied for the treatment of infections other than CDAD. Fidaxomicin should only be used for the treatment of CDAD.
Prescribing Fidaxomicin in the absence of proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
FDA,2020.05
Fidaxomicin is primarily employed for the management of Clostridium difficile-as···【more】
Release date:2024-07-30Recommended:127
fidaxomicin, a pharmacological agent renowned for its efficacy against Clostridi···【more】
Release date:2024-07-30Recommended:104